EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

@article{Yardley2015EMERGEAR,
  title={EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.},
  author={Denise A Yardley and Robert Weaver and Michelle Melisko and M. N. Saleh and Francis P. Arena and Andres Forero and Tessa Cigler and Alison T Stopeck and Dennis L. Citrin and Ira Anton Oliff and Rebecca G. Bechhold and Randa Loutfi and Agustin A. Garcia and Scott Cruickshank and Elizabeth Crowley and Jennifer Green and Thomas R. Hawthorne and Michael Jay Yellin and Thomas A. Davis and Linda T. Vahdat},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 14},
  pages={1609-19}
}
PURPOSE Glycoprotein NMB (gpNMB), a negative prognostic marker, is overexpressed in multiple tumor types. Glembatumumab vedotin is a gpNMB-specific monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin E. This phase II study investigated the activity of glembatumumab vedotin in advanced breast cancer by gpNMB expression. PATIENTS AND METHODS Patients (n = 124) with refractory breast cancer that expressed gpNMB in ≥ 5% of epithelial or stromal cells by central… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Comprehen - sive molecular portraits of human breast tumours

  • J Crown, J O’Shaughnessy, G Gullo
  • Nature
  • 2012

Intracellular activationofSGN-35,apotentanti-CD30antibodydrug conjugate

  • NM Okeley, JB Miyamoto, X Zhang
  • Clin Cancer Res
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…